Testing the Effect of a Compound on SASP Recently, scientists discovered a new compound that seemed to be able to influence the SASP. They hypothesize that this compound could be beneficial for pat

Hypothesis: Our compound will reduce the SASP secreted by fibroblasts in response to aging. Rationale: Aging is associated with increased levels of senescence associated secretory phenotype (SASP) resulting in damage to tissue and cells. Our compound may be able to reduce the SASP levels, thus reducing the damage associated with aging. Methodology: We will isolate primary dermal fibroblasts from a patient who has been diagnosed as aged, and culture these cells in standard medium. Then we will divide our cells into two groups: test and control. The test group will be treated with our compound at varying concentrations. The control group will be treated with the same medium without the compound. Both groups will be incubated for 24 hours and then collected. The contents of the supernatants of both groups will then be quantified using ELISA to measure the SASP molecules (e.g., chemokines, cytokines, and growth factors). Quantification: SASP molecules will be quantified using ELISA. This method will allow us to measure the amount of SASP in the cell supernatants. Interpretation: To assess the effect of our compound on SASP, we will compare the levels of SASP in the test and control groups. If our compound reduces the levels of SASP in the test group, then we can conclude that it is effective in reducing SASP in aging fibroblasts.